| 2.67 -0.11 (-3.96%) | 04-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.27 | 1-year : | 3.81 |
| Resists | First : | 2.79 | Second : | 3.27 |
| Pivot price | 2.47 |
|||
| Supports | First : | 2.43 | Second : | 2.21 |
| MAs | MA(5) : | 2.69 |
MA(20) : | 2.48 |
| MA(100) : | 2.37 |
MA(250) : | 2.14 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 89.6 |
D(3) : | 91.5 |
| RSI | RSI(14): 61.5 |
|||
| 52-week | High : | 3.22 | Low : | 0.52 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SPRO ] has closed below upper band by 19.9%. Bollinger Bands are 83% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.8 - 2.82 | 2.82 - 2.83 |
| Low: | 2.59 - 2.61 | 2.61 - 2.62 |
| Close: | 2.64 - 2.67 | 2.67 - 2.69 |
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Wed, 08 Apr 2026
Spero Therapeutics (SPRO) price target decreased by 20.00% to 4.08 - MSN
Mon, 06 Apr 2026
SPRO Forecast, Price Target & Analyst Ratings | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Sat, 28 Mar 2026
Spero Therapeutics (SPRO) Earnings Turn Positive Challenging Bearish Profitability Narratives - simplywall.st
Thu, 26 Mar 2026
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update - GlobeNewswire
Thu, 26 Mar 2026
Spero’s oral UTI antibiotic faces FDA decision on June 18 - Stock Titan
Wed, 11 Feb 2026
Spero Therapeutics: Tebipenem’s FDA Path Supports A Speculative Buy (NASDAQ:SPRO) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 58 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 22.5 (%) |
| Held by Institutions | 16.7 (%) |
| Shares Short | 537 (K) |
| Shares Short P.Month | 716 (K) |
| EPS | 0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.46 |
| Profit Margin | -108.2 % |
| Operating Margin | -134.7 % |
| Return on Assets (ttm) | -29.8 % |
| Return on Equity (ttm) | -95.4 % |
| Qtrly Rev. Growth | -59.6 % |
| Gross Profit (p.s.) | -0.37 |
| Sales Per Share | 0.7 |
| EBITDA (p.s.) | -0.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | 17.79 |
| PEG Ratio | 0 |
| Price to Book value | 5.68 |
| Price to Sales | 3.81 |
| Price to Cash Flow | -5.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|